Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by Red~Oneon May 13, 2022 8:55pm

189 Views

Post# 34683378

Yikes

From the 04/29 NR that wasn't really a NR....“…..the Issuer had to make the difficult decision to use funds earlier earmarked for the balance of the audit fee to be allocated instead for research and development expenses for the Company's ongoing Phase 1 clinical study in Australia. If it had not done so it would have faced research and development delays."

What does this mean ; " for the Company's ongoing Phase 1 clinical study in Australia." Where is the confirmation that Phase 1 is started? C'mon Bob

<< Previous

Bullboard Posts

Next >>

Gold, growth and sustainability in focus for Mandalay Resources